• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    5/10/23 5:39:59 PM ET
    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKYA alert in real time by email

    Gainers

    • Ampio Pharmaceuticals (AMEX:AMPE) stock increased by 38.6% to $0.28 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 4.2 million shares, which is 2348.4 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million.
    • Organogenesis Hldgs (NASDAQ:ORGO) stock increased by 19.04% to $2.5. Today's trading volume for this security ended up closing at 380.2K shares, which is 29.2 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $328.0 million. As per the press release, Q1 earnings came out today.
    • Semler Scientific (NASDAQ:SMLR) shares moved upwards by 14.06% to $27.66. The market value of their outstanding shares is at $189.3 million. The company's, Q1 earnings came out today.
    • Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 13.01% to $6.25. The company's market cap stands at $48.4 million.
    • Bellerophon Therapeutics (NASDAQ:BLPH) stock rose 12.51% to $9.71. The company's market cap stands at $101.4 million.
    • Akoya Biosciences (NASDAQ:AKYA) shares increased by 9.42% to $7.2. The market value of their outstanding shares is at $276.4 million. As per the press release, Q1 earnings came out 2 days ago.

    Losers

    • Vyant Bio (NASDAQ:VYNT) stock declined by 13.7% to $0.32 during Wednesday's after-market session. The market value of their outstanding shares is at $2.0 million.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares fell 13.42% to $0.58. Matinas BioPharma Hldgs's trading volume hit 144.2K shares by close, accounting for 38.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $126.0 million. As per the press release, Q1 earnings came out today.
    • Healthcare Triangle (NASDAQ:HCTI) shares decreased by 10.94% to $0.28. Healthcare Triangle's trading volume hit 111.1K shares by close, accounting for 24.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.1 million. As per the press release, Q1 earnings came out yesterday.
    • CareDx (NASDAQ:CDNA) stock fell 9.9% to $7.74. The market value of their outstanding shares is at $416.3 million. As per the press release, Q1 earnings came out today.
    • Erytech Pharma (NASDAQ:ERYP) stock decreased by 8.41% to $1.09. At the close, Erytech Pharma's trading volume reached 420.0K shares. This is 344.7% of its average volume over the last 100 days. The company's market cap stands at $33.8 million.
    • BioLife Solns (NASDAQ:BLFS) shares fell 8.12% to $17.1. The company's market cap stands at $738.9 million. The company's, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKYA
    $AMPE
    $BLFS
    $BLPH

    CompanyDatePrice TargetRatingAnalyst
    CareDx Inc.
    $CDNA
    1/6/2026$26.00Buy → Hold
    Craig Hallum
    CareDx Inc.
    $CDNA
    8/26/2025Mkt Perform
    William Blair
    Semler Scientific Inc.
    $SMLR
    7/28/2025Overweight
    Cantor Fitzgerald
    BioLife Solutions Inc.
    $BLFS
    7/22/2025$30.00Overweight
    Stephens
    Semler Scientific Inc.
    $SMLR
    7/8/2025$101.00Buy
    The Benchmark Company
    CareDx Inc.
    $CDNA
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    Akoya BioSciences Inc.
    $AKYA
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    BioLife Solutions Inc.
    $BLFS
    9/30/2024$29.00Buy
    H.C. Wainwright
    More analyst ratings

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

    BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on April 2, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' 

    4/3/26 5:00:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative

    CHANGZHOU, China, March 11, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that its Board of Directors has approved an 1-for-20 share combination of all its authorized and issued ordinary shares (the "Stock Combination") pursuant to the authorization granted from an extraordinary general meeting of the Company's shareholders on January 30, 2026 (the "EGM"). Effective as of the date of the EGM, the Company's authorized share capital is reclassified into a dual class of Class A ordinary shares

    3/11/26 7:30:00 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Healthcare Triangle, Inc. Announces Approval of $2 Million Share Repurchase Plan

    PLEASANTON, Calif., March 11, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announces that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $2,000,000 of its outstanding common stock ("2026 Share Repurchase Plan"). The 2026 Share Repurchase Plan was approved by the Company's Board of Directors on March 9, 2026, and became effective immediately. Under the newly authorized plan, the Company may repurchase shares of its common stock from tim

    3/11/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CareDx downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $26.00

    1/6/26 9:07:34 AM ET
    $CDNA
    Medical Specialities
    Health Care

    William Blair initiated coverage on CareDx

    William Blair initiated coverage of CareDx with a rating of Mkt Perform

    8/26/25 8:17:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    Cantor Fitzgerald initiated coverage on Semler Scientific

    Cantor Fitzgerald initiated coverage of Semler Scientific with a rating of Overweight

    7/28/25 9:00:02 AM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hanna John Walter Jr

    4 - CareDx, Inc. (0001217234) (Issuer)

    4/3/26 4:05:04 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Kennedy Keith

    4 - CareDx, Inc. (0001217234) (Issuer)

    4/3/26 4:04:27 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Meng Jessica

    4 - CareDx, Inc. (0001217234) (Issuer)

    4/3/26 4:03:39 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    SEC Filings

    View All

    Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    4/3/26 5:00:36 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by Healthcare Triangle Inc.

    NT 10-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    3/31/26 5:25:02 PM ET
    $HCTI
    EDP Services
    Technology

    SEC Form 10-K filed by Matinas Biopharma Holdings Inc.

    10-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    3/31/26 4:05:50 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 5:45:41 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

    Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac

    2/24/26 5:15:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

    Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation

    10/27/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

    Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-yearGAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarterGAAP net income of $2.1 million or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarterExpects 2026 revenue growth of $112.5 million to $115.0 million, up 17%-20% over 2025Conference call begins at 4:30 p.m. Eastern time todayBOTHELL, Wash., Feb. 26, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and serv

    2/26/26 4:03:00 PM ET
    $BLFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m. Eastern Time on February 26th to discuss the results of the quarter and the fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live w

    2/19/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKYA
    $AMPE
    $BLFS
    $BLPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care